Diaceutics remains 'well positioned' following strong sales performance

Data analytics and implementation services firm Diaceutics said on Monday that it had continued to trade in line with market expectations throughout the six months ended 30 June.

Diaceutics said it remained well positioned in key markets, underpinned by a "strong" sales performance.

The AIM-listed group also credited an increased international footprint for enhancing its global offering and allowing the company to acquire new international clients.

The Belfast-based outfit also said its Nexus project, the group's proposed software-as-a-service platform, was "progressing as planned".

Diaceutics, which expects to announce its full interim results in early September, said all outstanding debts had now been "retired" from its balance sheet, resulting in net cash of £14m.

As of 1010 BST, Diaceutics shares were up 2.96% at 87p.